Gliptins linked to arthralgia, FDA warns
The DPP-4 inhibitor drugs for type 2 diabetes may cause severe and disabling arthralgia, the FDA has warned, though Australian specialists say it is a rare adverse event.
The US regulator has added a warning about severe joint pain to the labels of gliptins after receiving 33 reports of the adverse effect associated with their use.
The joint pain was severe enough to be disabling and occurred anything from one day to several years after patients started taking a DPP-4 inhibitor, but stopped in less than a month when the patients discontinued the drug.
Joint pain recurred when patients